In this online CME self-learning program:
Alpha 1-antitrypsin (AAT) is a serine protease inhibitor produced in the liver which is responsible for protecting the lungs by inhibiting neutrophil elastase, an enzyme that destroys connective tissue within the lung. Alpha 1-antitrypsin deficiency (AATD) is a genetic disorder in which diminished concentrations of AAT result in the eventual degradation of alveoli, reducing pulmonary elastic recoil and airflow. Breakdown of the alveoli eventually manifest as emphysema or other forms of chronic lung disease. Other complications associated with AATD include liver disease, panniculitis, and vasculitis. The most common cause of death in patients with AATD is respiratory failure which accounts for 45 to 72% of deaths. Smoking, occupational hazards such as firefighting, and high levels of cumulative exposure to pollution accelerate the rate of lung function decline in people with AATD. AATD is estimated to affect one out of every 2,000 to 5,000 individuals, mainly of North European or Iberian ancestry. In sum, the disease is thought to affect approximately 190,000 people worldwide.
The following healthcare professionals: pulmonologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in pulmonology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with AATD.
This program is supported by an educational grant from Grifols
Release Date: June 26, 2017 -- Expiration Date: June 26, 2019
Faculty: Terese Hammond, MD
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Terese Hammond, MD has no relevant conflicts of interest to disclose.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Grifols
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Treatment strategies in Gaucher disease
Primary Immunodeficiency: Updates to Screening & Treatment
Treatment strategies in Hunter Syndrome
Systemic Sclerosis Interstitial Lung Disease (SSc-ILD): Optimizing Treatment Strategies